FDA Authorizes Organ-Chip Drug Tests, But Adoption Faces Culture Gap

Harvard researchers developed a lung-on-a-chip system more than a decade ago—a device smaller than a USB stick containing human lung cells arranged in channels that mimic breathing and respond to drugs or pathogens like living lungs would. When the team initially submitted their findings, Science journal editors asked them to validate results against mouse experiments, a request that reflected how thoroughly animal testing had dominated biomedical research.

Regulatory barriers have begun falling. The FDA Modernization Act 2.0, passed in late 2022, explicitly authorized alternatives to animal testing for drug preclinical studies. The FDA subsequently pledged in 2025 to make animal studies exceptional rather than routine. Researchers have developed organ-on-chip systems for the lung, brain, heart, kidney, and placenta, with some configurations linking up to 10 organs together to simulate human physiology more accurately than animal models. These are augmented by computational simulations and artificial intelligence tools that analyze experimental data.

Mass adoption remains limited. Validating and standardizing these alternatives requires rigorous head-to-head comparison with traditional methods. More fundamentally, Thomas Hartung, director of Johns Hopkins’ Center for Alternatives to Animal Testing, notes the real obstacle is organizational change—new policies, training, and institutional culture. Though pharmaceutical companies increasingly use alternatives internally and regulators now demand them, shifting established research practices across the industry remains the deepest challenge.